Arizona Cardinals defensive end Kareem Martin 96

Posted On Aug 11 2019 by

first_imgArizona Cardinals defensive end Kareem Martin (96) sacks St. Louis Rams quarterback Austin Davis to cause a fumble for a touchdown during the second half of an NFL football game, Sunday, Nov. 9, 2014, in Glendale, Ariz. (AP Photo/Ross D. Franklin) Derrick Hall satisfied with D-backs’ buying and selling Former Cardinals kicker Phil Dawson retires “I just wanted to go out there and do everything right. Have my right angle, have good get-offs, setting edges because this is a zone team—they hit the edge,” he said of the Bears, “and get after the passer standing on the edge and I felt like I accomplished that.”Martin, 25, has made plays in all three of the Cardinals’ preseason games. He had three tackles and a pass defensed in the Hall of Fame Game and then registered a half-sack and tackle for loss last week against Oakland.Martin is playing how he’s practiced, according to head coach Bruce Arians.“He’s been outstanding,” Arians said recently. “He’s another guy that kind of became our best special teams player. His pass-rush skills as his strength has gotten better. For him, standing up, that took some time having always played with his hand down. But, he’s got that length and he’s got a couple of good pass-rush moves now so, yeah, he’s earning his stripes.”A defensive end in college, Martin, who stands 6-foot-6 and weighs 272 pounds, transitioned to outside linebacker in 2015, after his rookie year. In the two seasons since, he’s made 16 tackles and 2.5 sacks in 29 games.“My pass rushing and just having overall confidence in myself to go out there and complete the task,” he said, referring to his progress. “This being my third year now at the position, I feel so much more comfortable doing every thing that Coach Bob (Sanders) and Coach (James) Bettcher ask me to do in the defense, and that’s the biggest thing when you’re playing outside backer because there’s so much to do.” The 5: Takeaways from the Coyotes’ introduction of Alex Meruelo Top Stories Besides Martin, the other outside linebackers in training camp looking for playing time behind Golden and Jones are Alex Bazzie, Cap Capi, Jarvis Jones and Terrence Waugh. Jones is the only one with an NFL resume, though, having played the past four seasons in Pittsburgh. But Jarvis Jones has been dealing with a back issue, keeping him on the sidelines for much of camp.In other words, Martin appears to be the clear front-runner to be that third outside linebacker.“He is right now,” Arians said. “Jarvis isn’t practicing, so he’s winning that job.”It would be quite the story: from special teams standout to key contributor defensively. It’s a story Martin hopes is written in 2017.“The biggest thing is just make an impact, on special teams and hopefully being that guy on that third down sub package to be able to rush the passer with my guys out there. That’s the biggest thing,” he said. “That was my goal coming in, to be able to get in that third-down package. I’m trying to showcase it in camp and in the games that I can be out there and be dependable, be that third guy they can depend on.”Follow Craig Grialou on Twitter GLENDALE, Ariz. – With Markus Golden on one side and Chandler Jones on the other, the Arizona Cardinals are set at outside linebacker; and perhaps for quite some time. Golden is 26 and eligible for a contract extension after this season, while Jones, 27, was just rewarded with a five-year deal back in March.But those two, who had a combined 23.5 sacks last season, can’t play every snap of every game; and often a third linebacker is used on the outside, especially in obvious passing situations. That third backer was Alex Okafor in 2016. He, however, departed in the offseason, signing a free-agent contract with the New Orleans Saints.The most likely player to step into that role in 2017 is Kareem Martin.“Definitely that’s the goal,” he said, following Saturday’s preseason loss to the Chicago Bears. “We got two great pass rushers in Markus and Chandler, so hopefully I can take over that spot that Okafor left here and continue what we had last year to be the top outside linebacker sack leaders in the NFL.”Against the Bears, Martin nearly had a sack and perhaps would’ve if it weren’t for a botched snap by center Taylor Boggs. Quarterback Mark Sanchez recovered the football and Martin, in on the play immediately, was credited with a one-yard tackle for loss.“I felt like if he didn’t fumble the ball I would have had a cleaner hit on him,” Martin said. “I felt like I had a good get-off. I jumped the snap it felt like, got around the edge. I beat the guy a few plays earlier so I knew I was going to be able to run around him and he just happened to fumble that when I was lucky to get my hands on him.”It was another solid effort by Martin, who also recorded a quarterback hit during his 19 defensive snaps. 1 Comments   Share   Grace expects Greinke trade to have emotional impactlast_img read more

Mylan Ranks No 2 In Executive Pay Among Drug Companies Far Outpacing

Posted On Jul 22 2019 by

first_img tween 2010 and early 2015, the prices of generic drugs provided under Medicare Part D for declined by nearly 60 percent – dramatic savings that helped leaven U.S. health care costs, according to a new report by the General Accountability Office (GAO). Generic drugs have long served as a counter-weight to pricey brand name prescription drugs. While they account for 88 percent of the 4.3 billion prescription drugs dispensed annually, they represent only 28 percent of the total price, according to industry experts. (Pianin, 9/14) The Wall Street Journal: EpiPen Maker Dispenses Outsize Pay The drugmaker buffeted by the furor over hefty price increases on its lifesaving EpiPen had the second-highest executive compensation among all U.S. drug and biotech firms over the past five years, paying its top five managers a total of nearly $300 million, according to a Wall Street Journal analysis. The big pay packages are unusual because of Mylan NV’s relatively small size in the U.S. drug industry, where it is No. 11 by revenue and No. 16 by market capitalization. (Maremont, 9/13) Amid the ongoing debate over the wisdom of pharmaceutical advertising, a new analysis suggests that doctors agree more often than not to write prescriptions for patients who have seen drug ads. At the same time, however, the analysis also found that only 1 in 10 consumers were moved by such advertising to ask a doctor for a prescription.The results present a slightly conflicting picture of the extent to which so-called direct-to-consumer advertising poses an unhealthy dilemma, according to the authors of the analysis, published Tuesday in the Journal of Clinical Psychiatry. While the pharmaceutical industry insists its ads educate consumers, doctors argue some ads too often encourage patients to seek medicines unnecessarily. (Silverman, 9/13) Stat: All That Pharmaceutical Advertising May Be A ‘Mixed Bag,’ After All Mylan Ranks No. 2 In Executive Pay Among Drug Companies, Far Outpacing Others Its Size The top five managers took home almost $300 million over the past five years, The Wall Street Journal reports amid continuing questions about the manufacter’s EpiPen pricing. News outlets also report on an FDA warning to doctors about drug risks, the pros and cons of pharmaceutical ads and a drop in the cost of generics. In case you missed it: Check out our weekly feature, Prescription Drug Watch, which includes coverage and perspectives of the issue. The Fiscal Times: Generic Drug Prices Dropped By Nearly 60% Under Medicare Part D The U.S. Food and Drug Administration has a message for doctors: The money you’re taking from pharmaceutical companies may be clouding your judgment. Research sites where Pfizer Inc. had paid doctors at least $25,000 in speaking, consulting or other fees reported sunnier results for its smoking-cessation drug Chantix, the FDA disclosed Monday. At those sites, doctors studying the drug’s possible link to suicide risk and other behavior changes reported fewer side effects than at locations where colleagues accepted lower or no payments. (Edney, 9/13) This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription. Bloomberg: Doctors Downplaying Drug’s Suicide Risks Attract FDA’S Scrutiny  last_img read more